Prostate-specific membrane antigen expression in regeneration and repair

Modern Pathology

Volumn 21, Issue 12, 2008, Pages 1421-1427

  Gordon, Ilyssa O ^a   Tretiakova, Maria S ^a   Noffsinger, Amy E ^a   Hart, John ^a   Reuter, Victor E ^b   Al Ahmadie, Hikmat A ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrium; Folic acid; Immunohistochemistry; Neovasculature; PSMA; Vasculogenesis

Indexed keywords

FOLIC ACID; FORMALDEHYDE; GAMMA GLUTAMYL HYDROLASE; PARAFFIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; DYSPLASIA; ENDOMETRIUM; ENZYME ACTIVITY; GRANULATION TISSUE; HEART VALVE; HUMAN; HUMAN CELL; HUMAN TISSUE; KELOID; PLEURA; PRIORITY JOURNAL; SCAR; TISSUE REGENERATION; TISSUE REPAIR; VASCULARIZATION;

BARRETT ESOPHAGUS; BLOOD VESSELS; ENDOMETRIUM; FEMALE; GRANULATION TISSUE; HUMANS; IMMUNOHISTOCHEMISTRY; KELOID; MALE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PRECANCEROUS CONDITIONS; PROSTATE-SPECIFIC ANTIGEN; REGENERATION;

EID: 56649083670     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.143     Document Type: Article

References (42)

1. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749-753.
2. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-1451.
3. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
4. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261.
5. Troyer JK, Beckett ML, Wright Jr GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
6. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
7. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50:472-483.
8. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-3634.
9. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
10. Al-Ahmadie HA, Olgac S, Gregor PD, et al. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol 2008;21:727-732.
11. Godeiro KD, Frota AC, Antecka E, et al. Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane. J Carcinog 2006;5:21.
12. Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-1134.
13. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003;170:S84-S88; discussion S88-89.
14. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25:540-547.
15. Mints M, Blomgren B, Falconer C, et al. Expression of the vascular endothelial growth factor (VEGF) family in human endometrial blood vessels. Scand J Clin Lab Invest 2002;62:167-175.
16. Mints M, Jansson M, Sadeghi B, et al. Endometrial endothelial cells are derived from donor stem cells in a bone marrow transplant recipient. Hum Reprod 2008;23:139-143.
17. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg 2005;39:293-306.
18. Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681.
19. Aghi M, Chiocca EA. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 2005;12:994-1005.
20. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
21. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007;117:1219-1222.
22. Zammaretti P, Zisch AH. Adult 'endothelial progenitor cells'. Renewing vasculature. Int J Biochem Cell Biol 2005;37:493-503.
23. Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007;117:1249-1259.
24. Caplice NM, Doyle B. Vascular progenitor cells: origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. Stem Cells Dev 2005;14:122-139.
25. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004;10:143-145.
26. Bhandari V, Choo-Wing R, Chapoval SP, et al. Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc Natl Acad Sci USA 2006;103:11021-11026.
27. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-2044.
28. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-2634.
29. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998;101:2567-2578.
30. Sasaki K, Duan J, Murohara T, et al. Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation. J Am Coll Cardiol 2003;42:364-372.
31. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 2007;113:47-63.
32. Das U. A radical approach to cancer. Med Sci Monit 2002;8:RA79-RA92.
33. Marikovsky M, Nevo N, Vadai E, et al. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 2002;97:34-41.
34. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:6-13.
35. Moat SJ, Lang D, McDowell IF, et al. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 2004;15:64-79.
36. Quinlivan EP, Hanson AD, Gregory JF. The analysis of folate and its metabolic precursors in biological samples. Anal Biochem 2006;348:163-184.
37. Anilkumar G, Barwe SP, Christiansen JJ, et al. Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature. Microvasc Res 2006;72:54-61.
38. Garcia-Cardena G, Fan R, Stern DF, et al. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 1996;271:27237-27240.
39. Goligorsky MS, Li H, Brodsky S, et al. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 2002;283:F1-F10.
40. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006;26:5310-5324.
41. Sihvo EI, Ruohtula T, Auvinen MI, et al. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. J Thorac Cardiovasc Surg 2003;126:1952-1957.
42. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170:1717-1721.